Optimizing tumor immune response through combination of radiation and immunotherapy

dc.contributor.authorEl-Chediak, Alissar
dc.contributor.authorShamseddine, Ali I.
dc.contributor.authorBodgi, Larry
dc.contributor.authorObeid, Jean Pierre
dc.contributor.authorGeara, Fady B.
dc.contributor.authorZeidan, Youssef H.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentRadiation Oncology
dc.contributor.departmentDivision of Hematology Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:49:48Z
dc.date.available2025-01-24T11:49:48Z
dc.date.issued2017
dc.description.abstractRadiation therapy and immunotherapy are two highly evolving modalities for the treatment of solid tumors. Immunotherapeutic drugs can either stimulate the immune system via immunogenic pathways or target co-inhibitory checkpoints. An augmented tumor cell recognition by host immune cells can be achieved post-irradiation, as irradiated tissues can release chemical signals which are sensed by the immune system resulting in its activation. Different strategies combining both treatment modalities were tested in order to achieve a better therapeutic response and longer tumor control. Both regimens act synergistically to one another with complimentary mechanisms. In this review, we explore the scientific basis behind such a combination, starting initially with a brief historical overview behind utilizing radiation and immunotherapies for solid tumors, followed by the different types of these two modalities, and the biological concept behind their synergistic effect. We also shed light on the common side effects and toxicities associated with radiation and immunotherapy. Finally, we discuss previous clinical trials tackling this multimodality combination and highlight future ongoing research. © 2017, Springer Science+Business Media, LLC.
dc.identifier.doihttps://doi.org/10.1007/s12032-017-1025-z
dc.identifier.eid2-s2.0-85027860181
dc.identifier.pmid28828581
dc.identifier.urihttp://hdl.handle.net/10938/30911
dc.language.isoen
dc.publisherHumana Press Inc.
dc.relation.ispartofMedical Oncology
dc.sourceScopus
dc.subjectAbscopal
dc.subjectImmunotherapy
dc.subjectRadiation
dc.subjectSbrt
dc.subjectClinical trials as topic
dc.subjectCombined modality therapy
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectRadiotherapy
dc.subjectTreatment outcome
dc.subjectImmunomodulating agent
dc.subjectCancer immunotherapy
dc.subjectCancer radiotherapy
dc.subjectHuman
dc.subjectMultimodality cancer therapy
dc.subjectNonhuman
dc.subjectPhase 1 clinical trial (topic)
dc.subjectPhase 2 clinical trial (topic)
dc.subjectPriority journal
dc.subjectRadiation injury
dc.subjectRadiation response
dc.subjectReview
dc.subjectSolid malignant neoplasm
dc.subjectT lymphocyte activation
dc.subjectTreatment response
dc.subjectTumor escape
dc.subjectTumor immunity
dc.subjectUnspecified side effect
dc.subjectClinical trial (topic)
dc.subjectNeoplasm
dc.subjectProcedures
dc.titleOptimizing tumor immune response through combination of radiation and immunotherapy
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2017-8703.pdf
Size:
507.66 KB
Format:
Adobe Portable Document Format